Labrie F, et al. - Researchers conducted this phase 3 prospective, randomized, double-blind, placebo-controlled study to determine the potential beneficial effects of intravaginal dehydroepiandrosterone (DHEA; prasterone) on moderate to severe dyspareunia or pain at sexual activity—the most frequent symptom of vulvovaginal atrophy due to menopause or genitourinary syndrome of menopause (GSM). They examined the effect of daily intravaginal 0.50% DHEA (6.5 mg) on four coprimary objectives: percentage of parabasal cells, percentage or superficial cells, vaginal pH, and moderate to severe pain at sexual activity (dyspareunia). Outcomes revealed that the treatment had clinically and highly statistically significant effects on the four coprimary parameters. The study drug was found to have strictly local action that is in line with the absence of significant drug-related adverse events, indicative of a high benefit-to-risk ratio.